XG-102

Phase 3Small molecule

XXigen SA

XG-102 is one of 30 small molecule programs targeting Cataract. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CataractActive, not recruiting

CataractPhase 3

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Phase 3

1 2

Ripasudil

KKowa Research Institute, Inc.

Phase 3

2 3

Idose TR

GGlaukos Corporation

Phase 3

1 4

OCS-01

QQuan Dong Nguyen

Phase 3

1 5

XG-102

XXigen SA

Phase 3

2 6

Midalozam

Idorsia Pharmaceuticals Ltd.

Phase 3

2 7

Zolymbus

AbbVie

Preclinical

—8

Neurontin

VViatris Specialty LLC

Preclinical

3 9

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cataract2 trials

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Completed·XXigen SA·Phase 3·NCT02235272·339 enrolled

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

Completed·XXigen SA·Phase 3·NCT02508337·309 enrolled

Infusion1 trial

Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers

Completed·XXigen SA·Phase 1·NCT01570205·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for XG-102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XG-102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XG-102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xigen SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: XXigen SA

XG-102

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cataract2 trials

Infusion1 trial

References

Drug Info

Quick Facts

Related News